One quarter after announcing a disappointing book-to-bill ratio, CRO Parexel has now renewed its strategic partnership with GlaxoSmithKline and seen its book-to-bill ratio jump to its highest level since 2012.
Revenues from Pall’s biopharmaceuticals division grew in fiscal 2009, excluding foreign currency changes, with the company benefiting from the “thriving market” for vaccines and expanding adoption of single-use systems.
Dutch chemicals and drugs group Akzo Nobel saw its net income
accelerate in the third quarter of this year, to the surprise of
analysts and investors, and helped by cost reductions and a big
gain from the divestment of its coatings...